Mereo BioPharma (MREO) Profit After Tax (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Profit After Tax of -$8.5 million for Q1 2026, up 34.3% year-over-year from -$6.3 million in Q1 2025, and down 15.18% quarter-over-quarter from -$7.4 million in Q4 2025.
Mereo BioPharma (MREO) Profit After Tax (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Profit After Tax for 4 consecutive years, with -$8.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 34.3% year-over-year to -$8.5 million; the TTM figure through Mar 2026 stood at -$39.7 million (up 18.18% YoY), while the FY2025 annual figure was -$41.9 million, up 6.14% from the prior year.
- Profit After Tax slipped to -$8.5 million in Q1 2026 per MREO's latest filing, from -$7.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$1.8 million in Q2 2023 and bottomed at -$15.0 million in Q3 2024.
- Historically, Profit After Tax has averaged -$10.0 million across 4 years, with a median of -$9.3 million in 2025.
- Annual changes were most pronounced in 2024 — Profit After Tax sank 599.89% — and 2025, when it soared 38.06%.
- Mereo BioPharma's Profit After Tax stood at -$9.1 million in 2023, then advanced by 7.67% to -$8.4 million in 2024, then gained by 12.59% to -$7.4 million in 2025, then fell by 15.18% to -$8.5 million in 2026.
- Business Quant data shows MREO's Profit After Tax at -$8.5 million in Q1 2026, -$7.4 million in Q4 2025, and -$9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | -7.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.01 Mn |
| Mar 31, 2026 | -8.47 Mn |
| Dec 31, 2025 | -7.35 Mn |
| Sep 30, 2025 | -9.29 Mn |
| Jun 30, 2025 | -14.62 Mn |
| Mar 31, 2025 | -12.89 Mn |
| Dec 31, 2024 | -8.41 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | -12.26 Mn |
| Mar 31, 2024 | -8.95 Mn |
| Dec 31, 2023 | -9.11 Mn |
| Sep 30, 2023 | -10.11 Mn |
| Jun 30, 2023 | -1.75 Mn |
| Mar 31, 2023 | -12.08 Mn |